OncoMatch/Clinical Trials/NCT06407947
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Is NCT06407947 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Chimeric antigen receptor modified T cells Infusion for multiple myeloma.
Treatment: Chimeric antigen receptor modified T cells Infusion — This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 deletion (17p)
Meet any one or more of the cytogenetic criteria: del (17p)
Required: IGH t(4;14)
Meet any one or more of the cytogenetic criteria: t (4; 14)
Required: IGH t(14;16)
Meet any one or more of the cytogenetic criteria: t (14; 16)
Required: IGH t(14;20)
Meet any one or more of the cytogenetic criteria: t (14; 20)
Required: CKS1B 1q21 amplification ≥ 4 copies
Meet any one or more of the cytogenetic criteria: 1q21 amplification ≥ 4 copies
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Exception: up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Cannot have received: proteasome inhibitor
Exception: up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Cannot have received: immunomodulator
Exception: up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Cannot have received: targeted therapy
Exception: up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Cannot have received: radiation therapy
Exception: patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Cannot have received: epigenetic therapy
Exception: up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction
Prior treatment for MM other than up to 2 cycles of (bortezomib, lenalidomide, dexamethasone) for induction, including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy (patients are eligible for this trial if the radiation field covers ≤ 5% bone marrow reserve regardless of the end date of radiotherapy), epigenetic therapy, etc.
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L; Platelet ≥ 50 × 10^9/L; Hemoglobin ≥ 7.5 g/dL
Kidney function
Endogenous creatinine clearance ≥ 40 mL/min
Liver function
ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN
Cardiac function
No uncontrolled congestive heart failure (NYHA III/IV), myocardial infarction, CABG or unstable angina within 6 months prior to apheresis, no history of clinically significant uncontrolled cardiac arrhythmias, severe non-ischemic cardiomyopathy, LVEF < 50%, or other significant heart disease
Hematology: Absolute neutrophil (ANC) count ≥ 1.0 × 10^9/L; Platelet (PLT) ≥ 50 × 10^9/L; Hemoglobin (Hb) ≥ 7.5 g/dL; Blood chemistry: Endogenous creatinine clearance ≥ 40 mL/min; ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN; Cardiac: see exclusion criteria 11
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify